{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-006460","form_type":"8-K","ticker":"IRMD","cik":"0001325618","company_name":"IRADIMED CORP","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.842274+00:00","generated_at":"2026-06-03T00:08:35.565838+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"IRADIMED reports record Q1 revenue of $17.6M, up 13.7% YoY; EPS $0.32 GAAP, $0.36 non-GAAP","bullets":["Q1 2024 record revenue $17.6M, +13.7% YoY; operating income $4.7M, +18.5%.","GAAP diluted EPS $0.32, non-GAAP $0.36; net income $4.1M, +21.4%.","Declared regular quarterly dividend of $0.15/share payable May 30, 2024 to holders of record May 20.","Q2 2024 guidance: revenue $17.6-17.8M, GAAP EPS $0.33-0.36, non-GAAP $0.36-0.39.","FY 2024 guidance reiterated: revenue $72-74M, GAAP EPS $1.37-1.47, non-GAAP $1.52-1.62."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-006460","json":"https://secwatch.observer/filing/0001558370-24-006460.json","markdown":"https://secwatch.observer/filing/0001558370-24-006460.md","text":"https://secwatch.observer/filing/0001558370-24-006460.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1325618/000155837024006460/0001558370-24-006460-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1325618/000155837024006460/irmd-20240502x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:08:35.565838+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6daf4caee254baddaec40fa233450a309d56b586","claim":"IRADIMED CORP reported the three months ended March 31, 2024 results: revenue $17.6 million, net income $4.1 million, EPS $0.32 per diluted share. Guidance reaffirmed.","evidence_excerpt":"IRADIMED CORPORATION Announces First Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share ● Reports record revenue of $17.6 million for the first quarter of 2024. ​ ● Reports GAAP diluted EPS of $0.32 and non-GAAP diluted EPS of $0.36 for the first quarter of 2024. ​ ● Reports first quarter of 2024 operating","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1325618/000155837024006460/0001558370-24-006460-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$17.6 million"},{"label":"Net income","value":"$4.1 million"},{"label":"EPS","value":"$0.32 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}